Washington is dismantling the pathway to the next cancer breakthrough

The U.S. Office of Management and Budget (OMB) proposed a rule on May 29 that would shift control of federal research funding from scientists to political appointees. The policy requires approval from appointees for grant recipients and downgrades peer review to advisory status, allowing agencies to ignore it. It also permits the government to cancel grants already awarded if projects are deemed no longer in the federal interest, with the rule set to take effect October 1. Public comments on the proposal are due by July 13. The rule is framed as an effort to improve oversight, but critics warn it politicizes science funding. A recent example of its potential consequences includes the cancellation of 22 mRNA vaccine projects worth nearly $500 million in August, targeting pandemic preparedness. The same administration previously promoted vitamin A as a measles treatment, leading to hospitalizations in Texas due to toxicity. The proposed changes threaten advancements like experimental mRNA vaccines for pancreatic cancer, which showed promising early trial results this spring. Fewer than 1 in 7 patients survive five years after diagnosis, making breakthroughs critical. A related melanoma vaccine has also demonstrated nearly halving the risk of recurrence, marking real progress after decades of setbacks. Industry-developed vaccines rely on federally funded research in RNA and immunology, including work recognized by the 2023 Nobel Prize in medicine. Public grants sustain university labs and the workforce behind these discoveries. The rule risks dismantling the research infrastructure that enables private-sector innovation, potentially stalling progress in cancer and other life-saving fields.